concentrations and functional parameters were present in three out of 11 cases in which plasma levels changed by at least 25 ng/ml during the investigational period and peak levels did not exceed 100 ng/ml. Several other observations indicated that pyridostigmine at levels above 100 ng/ml may impair neuromuscular function.
In the symptomatic treatment of myasthenia gravis with the anticholinesterase drug pyridostigmine, prescribed oral doses vary over a wide range, at least from 60 to 1500 mg/ day."2 Individual optimisation is required because doses that are too high may impair muscle strength due to an excess of acetylcholine. 3 In addition, the kinetics of orally administered pyridostigmine are complicated by low and variable availability.45 Dose adjustment with the aid of plasma concentrations is hampered by the lack of a commonly accepted therapeutic range of pyridostigmine concentrations. 6 Its establishment would require measurement of plasma concentrations in patients in parallel to an evaluation of the clinical state. The purpose of this study was to obtain data of this kind in a larger group of patients than those investigated previously. '7 Patients and methods Patient group The study included 11 female and seven male patients with generalised myasthenia. Six of them were investigated two or three times at intervals of two weeks to three years, so that a total of 27 investigations were carried out, but detailed functional evaluation was only possible in 26. Pharmacokinetic data from six of the patients were included in a previous publi- 16  11  m  54  240  60  43  69  12300  0-4  12  m  55  300  60  50  76  10700  3-8   13  m  63  120  40  59  70   -0-7   14/a   f  39  220  50  52  66  17800  2-0   8/b   f  64  320  80  46  63  12500   0 9  15  f  65  120  60  32  48  12000  2-8   16  f  78  140  35  60  72  17900  0 9   Group C  9/a   m  43  240  60  89  117  31650  3-3   10/a   m  53  240  60  54  135  13800  1-7  lb  53  240  60   97  127  24300  2-7   17  f   21  160  40  109 A pathological decrement of the trapezius muscle action potential was measured in 12 investigations in seven patients. Other patients either did not show an impairment of neuromuscular transmission or their clinical state did not allow them to carry out the measurement (three cases). The decrement that attained maximal values of -10 to -57% in the total group changed by at least 10% (maximum change 30%/-) in 10 cases.
Relationships between plasma concentrations and functional parameters
Because of the large differences between patients in their clinical state, no attempts were made to correlate plasma concentration and functional data in the group. Instead, data were checked for the existence of correlations within patients that would give a clue to therapeutically favourable plasma concentrations.
If the clinical state is expected to improve on raising the pyridostigmine plasma concentration, negative correlations should exist between the latter and the total score as well as the absolute value of the decrement. On the other hand, the HLT should correlate positively with plasma pyridostigmine.
Since no correlations could be expected in the absence of marked plasma concentration fluctuations, those investigations in which changes were below 25 ng/ml were placed in a separate group (A, N = 10); mean levels were below 50 ng/ml in eight of these cases and below 70 ng/ml in all of them. Moreover, for concentrations that were too high no further improvement can be expected to parallel an increase in the plasma level. Thus, a limit was tentatively set at 100 ng/ml and cases with higher peak concentrations combined as group C (N = 6). Group B (N = 11) comprised investigations in which plasma concentrations changed by 25 ng/ml or more, but did not exceed 100 ng/ml (table) .
Statistically significant correlations between plasma concentrations and HLT were present in three cases (9/c, 12, 15) , all of them belonging to group B. In cases 9/c and 15, significant correlations were also revealed with the total score and the decrement, respectively (fig 1) . No deteriorated at this time relative to the preceding and the following time points (fig 2) . Even in the cases with significant correlations, there was no complete agreement between time courses of plasma concentrations and functional data. For instance, in patient 15 , maximal improvement of all parameters preceded the peak pyridostigmine concentration by one hour, whereas the reverse applied in case 9/c (fig 1) .
A further indication of the unfavourable effect of high plasma pyridostigmine concentrations is the fact that patients 9 and 10 exhibited higher scores in the investigations where maximal levels exceeded 100 ng/ml than in those comprised in group B (table) . Moreover, the highest peak and mean pyridostigmine levels were observed in 14/b. At that time, no systematic investigation was possible due to the patient's poor clinical state. She had marked muscular weakness (HLT < 10 sec) and cholinergic overstimulation was apparent from sialorrhoea, bronchial hypersecretion and diarrhoea. Two weeks earlier, the same patient while receiving a somewhat lower pyridostigmine dose had had plasma concentrations in the intermediate range and had been in a much better condition (14/a in group B). centrations relative to daily dose by a factor of about five, which agrees with findings by previous investigators.2413 Major reasons for this can be assumed to be variabilities in the fraction absorbed and in the renal elimination rate. In healthy volunteers, areas under plasma concentration-time curves varied up to twofold on repeated testing with oral doses,5 and similar variations were observed in two patients of this series who were studied twice or three times. When the AUC values were adjusted to a 60 mg dose in the patient group, their mean was similar to that observed in healthy subjects,5 but interindividual variability was considerably higher.
Differences in mean plasma concentration/ dose ratios between patients receiving and not receiving glucocorticoid comedication could not be detected, a finding that conflicts with the observation that addition of prednisolone considerably reduced pyridostigmine availability.2 Clear cut pyridostigmine plasma concentration effect relationships were not established in any investigations including the present one, particularly when studies were carried out under conditions of routine treatment. In two out of four and two out of nine outpatients, significant associations were detected between plasma concentrations and electromyographic findings'4 or muscle strength,' respectively. Since this study comprised a larger and unselected patient group, the results appear to be comparable. Maximum measured concentrations in patients with significant correlations were between 48 and 85 ng/ml in the present series and between 10 and 77 ng/ml in the previous ones;' 14 the latter values have to be regarded as lower limits, because in the two investigations unbuffered plasma samples were stored at -20°C for unspecified lengths of time, so that pyridostigmine may have been partially hydrolysed.5
More consistent results were obtained on pyridostigmine administration to patients with myasthenia from whom medication had been withheld, so that drug plasma concentrations had declined to undetectable levels. In three patients given pyridostigmine iv, functional improvement occurred up to 30-60 ng/ml and functional impairment at higher levels.'2 Ingestion of 60-120 mg pyridostigmine by 10 patients resulted in high correlation coefficients between plasma concentrations and parameters of muscular function in some patients, but none of these achieved significance at the p < 0-05 level.7 Peak levels were below 90 ng/ml in all but one patient, and inspection of data from the latter discloses functional deterioration at levels of 100 and 125 ng/ml. Our data gives additional reasons to warn against high plasma concentrations, because the patient exhibiting the highest levels (peak 197 ng/ml, mean 117 ng/ml) showed not only cholinergic overstimulation, but also poor neuromuscular function. Moreover, two patients investigated repeatedly exhibited more impairment during periods with maximal concentrations above 100 ng/ml. It could be argued that patients with more severe disease required higher doses and therefore attained higher plasma levels, but this can be refuted, because doses did not differ among patient groups defined by mean or maximal plasma concentrations.
